Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Conditions:   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Oropharyngeal Cancer
Interventions:   Drug: Utomilumab;   Biological: ISA101b
Sponsors:   M.D. Anderson Cancer Center;   ISA Pharmaceuticals B.V.;   Pfizer
Not yet recruiting - verified August 2017

http://ift.tt/2vkF3DK